Trial Profile
PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Carboplatin (Primary) ; Avelumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PRIME002
- 18 Nov 2021 Planned number of patients changed from 30 to 40.
- 18 Nov 2021 Planned End Date changed from 31 Dec 2020 to 28 May 2023.
- 18 Nov 2021 Status changed from recruiting to discontinued.